Patients treated for renal cell carcinoma (RCC) may be diagnosed with a metachronous, contralateral tumor. We evaluated the risks of contralateral tumor development using the Surveillance, Epidemiology, and End Results database. METHODS: Among RCC patients, we identified those with a metachronous, contralateral RCC diagnosed ≥1 year after primary diagnosis. We performed a competing risks analysis to evaluate associations between clinicopathologic factors and metachronous, bilateral RCC. Cumulative incidence and standardized incidence ratios (SIRs) were calculated. RESULTS: There were 80,403 cases of RCC identified, with a median follow-up of 8.3 years; of these, 1063 (1.3%) developed metachronous, contralateral RCC (median of 6 years after diagnosis). The cumulative incidence at 10, 20, and 30 years of follow-up was 1.5%, 3.1%, and 4.7%, respectively. An increased risk was observed among men (hazard ratio [HR], 1.36; 95% confidence interval [CI], 1.20-1.55), blacks (HR, 2.00; 95% CI, 1.71-2.33), and those with papillary histology (HR, 1.72; 95% CI, 1.41-2.10). Risk of metachronous disease decreased with increasing age at primary diagnosis (HR per 1-year increase, 0.97; 95% CI, 0.96-0.97). The SIRs were highest among those diagnosed at a younger age and remained elevated even after extended follow-up (>10 years). CONCLUSIONS: Our findings suggest that the cumulative incidence of metachronous, contralateral RCC may be higher than previously reported. Younger age, black race, papillary histology, and male sex increase the risk of metachronous, contralateral RCC development. The high SIRs seen in all demographic groups may support a rationale for lifelong surveillance, especially in high-risk subgroups with early disease onset. Cancer 2019;125:232-238.
INTRODUCTION
The development of a renal cell carcinoma (RCC) has been associated with environmental exposures, genetic susceptibility, and some medical conditions. Many of these risk factors may predispose patients to the development of bilateral disease. Bilateral RCC may coexist at the time of diagnosis (synchronous), or develop subsequently (metachronous), sometimes years after the first primary tumor. 1 Overall, the cumulative incidence of metachronous bilateral RCC has been reported to be 0.4%-5%. [2] [3] [4] [5] [6] Regardless of whether it is metachronous, bilateral disease is a consequence of spread from the primary RCC or a de novo process is often debated; however, most experts consider a contralateral tumor to be a new primary RCC, especially without evidence of distant disease.
The risk of developing a contralateral tumor is greater when there is a family history of RCC or if the patient has a genetic cancer syndrome such as Von Hippel-Lindau disease. 4 Understanding these risks may determine appropriate surveillance following treatment and help guide therapy. Advocating for partial nephrectomy as management can become challenging if a contralateral tumor develops in a solitary kidney. In these instances, further surgical therapy may significantly increase the risk of chronic kidney disease and/or dialysis, both of which may shorten life expectancy.
Cancer January 15, 2019 Cases were identified by querying the SEER database for left-and right-sided RCC based on International Classification of Diseases for Oncology (3rd Edition) codes. Patients with a second new primary RCC diagnosis in the contralateral kidney were identified using the multiple primary malignant code in SEER. Using SEER patient identification codes, cases were cross-referenced and duplicates were removed. For patients with multiple second diagnoses of kidney cancer, the earliest diagnosis was used as the reference. Previously published International Classification of Diseases for Oncology (3rd edition) histologic/behavior codes were used to classify patients with RCC. 9 Only microscopically confirmed cases of RCC were included. To avoid synchronous bilateral tumors having staged surgical management, patients were excluded if their second diagnosis was within 1 year of primary diagnosis or if follow-up time was less than 12 months. Patients presenting with an initial diagnosis of distant disease, unknown stage, and unknown race were also excluded. Tumor size was available beginning in 1983. A flowchart of the case selection method is depicted in Supporting Figure 1 .
Chi-square and independent t tests were used to compare characteristics between patient groups. Oneway analysis of variance was performed to compare mean tumor sizes amongst groups of patients diagnosed with bilateral metachronous RCC at varying times. A Fine and Gray competing risks regression model was used to examine factors that predicted a new contralateral, metachronous kidney tumor with a competing risk of death. Statistical significance was set at α ≤ 0.05. Total person-years at risk for the development of a new contralateral tumor were calculated using months of follow-up and were stratified by age, race, and sex. The incidence rates of RCC (first diagnosis) age-adjusted to the 2000 US standard population were calculated using SEER*Stat 8.3.2 software. Separate incidence rates were obtained for year of diagnosis, race, sex, and age (using 5-year intervals) as described previously. 5 Incidence rates were then multiplied by person-years at risk among cases with a primary RCC diagnosis to calculate the number of expected new cases of metachronous RCC after primary diagnosis. The standardized incidence ratio (SIR) was calculated as the number of observed over the number of expected events, and 95% confidence intervals (CIs) were calculated. 10 To account for differences across registries, we also evaluated the SIR using the SEER-9 registry alone. The Nelson-Aalen estimate was used to assess the cumulative incidence of metachronous bilateral RCC over a 30-year follow-up period. All statistical analyses were performed using IBM SPSS Statistics version 22 and R version 3.3.0 along with the rms and cmprsk packages.
RESULTS
A total of 80,403 patients were identified; the demographic characteristics are shown in Cancer January 15, 2019 (62.3%) patients were men, and 30,283 (37.7%) were women. White, black, and other race represented 85.0%, 9.9%, and 5.0% of the population, respectively. Local and regional stages were 79.2% and 20.8% of cases, respectively. There were 1063 (1.3%) cases of metachronous contralateral tumors over 656,860 person-years of follow-up. Contralateral tumors were more common among blacks and among men (Table 1 ). In addition, those with contralateral tumors had primary RCC tumors diagnosed at a younger age (56 vs 62 years; P < .001), were larger (5 vs 4.5 cm; P < .001), and were of papillary histology (10.3% vs 6.5%)
The 10-, 20-, and 30-year cumulative incidence rates for metachronous, bilateral RCC were 1.5%, 3.1%, and 4.7%, respectively ( Fig. 1) . A competing risks analysis treating death as a competing event was performed to evaluate risk of metachronous bilateral RCC ( Supporting Table 1 lists the SIRs stratified by race, sex, age, and by each 5-year period of follow-up. Compared with patients without prior RCC, the SIRs for all patients regardless of category is significantly elevated (≥1) even after an extended follow-up. The log transformed SIRs are depicted in Figure 2 demonstrating that the SIRs are the highest for individuals diagnosed at a younger age. Even for individuals diagnosed at advanced age, the SIR remains significantly elevated.
The median time to a new contralateral kidney tumor was 6 years (IQR, 3.5-9.5 years). A total of 430 (40.5%) new contralateral kidney tumors were found within 5 years, 387 (36.4%) between 5 and 10 years, and 246 (23.1%) after 10 years of initial diagnosis (Fig. 3) . Mean tumor size for the contralateral RCC was greater a lesser stage, and 3.1% were not staged. For patients who had metachronous disease and grade data for both tumors (504 patients), 47.2% were the same grade, 28.6% were of a higher grade, and 24.2% were of a lower grade. Of patients who were initially treated with radical nephrectomy who developed a contralateral tumor, 21% (170/794) were rendered anephric due to a second radical nephrectomy, 49% (389/794) underwent partial nephrectomy, and 15% (119/794) did not have subsequent treatment (Supporting Table 2 ).
DISCUSSION
The findings from this large population-based analysis indicate the cumulative incidence of bilateral, metachronous RCC may be higher than previously estimated. Among patients with a primary diagnosis of RCC, the observed frequency of bilateral, metachronous RCC was 1.3%, and the estimated overall cumulative incidence at 30-year follow-up was 5%. Our study builds upon previous reports evaluating the incidence of metachronous, bilateral RCC. In 2002, Rabbani et al 5 assessed metachronous RCC using SEER and found a 0.4% overall cumulative incidence with a median follow-up of 2.3 years. A similar study by Wiklund et al 6 was performed using cancer registries from Norway and Sweden; that study similarly found an incidence of 0.4% and had a median follow-up of 4.4 years. Furthermore, they combined both registries and estimated the overall cumulative incidence at 25 years to be 0.8%, with an increase to 1.5% at 10 years if the initial diagnosis was made at <40 years of age. 6 Both prior series were limited by the median follow-up of less than 5 years, which might underestimate disease occurrence. 4, 11 To minimize inadequate follow-up, only patients diagnosed before 2008 with subsequent follow-up to 2013 were included. This resulted in a median follow-up time of 8.3 years and ensured that events could be captured. The definition of what constitutes a metachronous, bilateral RCC must be appropriately established before evaluating the incidence. It has been demonstrated previously that nearly half of bilateral RCC cases occur synchronously 11 and over a quarter of patients with synchronous, bilateral tumors may be treated with delayed surgical management (>6 months).
12 Both Rabbani et al 5 and Wiklund et al 6 used a 6-month cutoff to define metachronous disease, so it is likely a number of second tumor diagnoses captured between 6-12 months of follow-up actually represented synchronous, bilateral RCC treated in a staged manner. With this definition, the incidence of metachronous RCC may have been overestimated. We defined a metachronous event as having occurred ≥1 year from initial RCC diagnosis. This methodology allows for a more accurate representation of the true incidence of metachronous, bilateral RCC and explains the higher incidence seen.
Our findings are consistent with prior evidence supporting the increased incidence of an additional RCC when compared with the general population. 5, 6 Black individuals with RCC are at a substantial risk of developing a contralateral, metachronous RCC, because the SIR of this group was particularly high (20.7 after 5 years of follow-up for ages 40-44 years). This may be an underestimation given that the incidence rates of RCC used in our analysis were from patients with presumably 2 at-risk kidneys. As suggested by Wiklund et al, 6 the SIR may be twice what we report, because we considered only 1 kidney to be at risk for contralateral tumor development. Younger age, male sex, and papillary histology were also found to be independent predictors for a metachronous, contralateral RCC. Although the overall 10-year cumulative incidence was relatively low (3.1%), certain patients have a significantly increased risk.
For surveillance, the National Comprehensive Cancer Network advocates at least 5 years of surveillance following treatment for stage I-III RCC. 13 Because most distant relapses occur within 3 years, these guidelines provide an appropriate surveillance strategy for detection of recurrence in most patients. 13, 14 However, there is no mention of the development of de novo RCC. Our data suggest that a significant proportion of contralateral kidney tumors develop after the risk of systemic recurrence has greatly decreased and supports monitoring beyond current recommendations. This was illustrated in the current study, because 59.5% of patients with contralateral disease developed after 5 years and 23.1% were discovered ≥10 years after the primary diagnosis. Because the SIRs for a contralateral tumor remain significantly increased up to 15 years, lifelong follow-up may be considered. Our study did not specifically address the development of a de novo RCC in the ipsilateral kidney after a partial nephrectomy due to challenges in differentiating this from a local recurrence. However, evaluating the remaining portion of the kidney long-term would clearly have a similar benefit as the contralateral side. In fact, considering the additional risk of local recurrence, tumor development may be expected to be even higher on this side. Kidney cancer screening has not been advocated in the general population due to the low incidence of RCC and the questionable survival benefit of early detection. However, in RCC patients, data from our study and others consistently demonstrates that regardless of age, sex, race, or length of follow-up, the incidence of a subsequent contralateral RCC is considerably higher than that for the general population. 5, 6 Earlier detection may alter treatment by identifying tumors at a more localized stage. This is supported in that contralateral tumor size ≥10 years from diagnosis was significantly larger than those diagnosed earlier (4.1 vs 2.9 cm). Earlier detection may prevent the development of a more complex, contralateral kidney tumor that could preclude nephron-sparing surgery. This is especially important in patients who had a prior radical nephrectomy, because 16% of patients became anephric after treatment for a metachronous, contralateral RCC.
Understanding which patients are at the highest risk can help identify those with a more imperative indication for partial nephrectomy. For small, localized tumors, partial nephrectomy has equivalent oncologic outcomes, in addition to renal and cardiovascular benefits. 15, 16 Nevertheless, radical nephrectomy remains the most commonly performed surgery for small renal masses. 17 This observation is partly attributed to the technical challenges of partial nephrectomy and increased surgical complications. 17 Because certain subsets of patients are at a higher risk of developing contralateral disease, partial nephrectomy should be the initial treatment for any localized tumor amenable to nephron-sparing treatment. Active surveillance may also be a viable option for patients with small tumors who have a significant risk for metachronous RCC. In this population, whereas oncologic control is the main goal, it is also worth considering what could be done to minimize the number of partial nephrectomies in one's lifetime. Performing reoperative renal surgery (after a prior partial nephrectomy) has significant challenges and a high rate of complications. 18 In addition, there could be advantages to active surveillance in patients who have small tumors and are at risk for metachronous RCC, (ie, to limit the number of ipsilateral partial nephrectomy operations); however, this is a more relevant concern for ipsilateral rather than contralateral recurrences.
Our study is not without limitations, including those inherent to the use of a large, retrospective secondary database that does not provide access to detailed clinical information, such as comorbidities or tumor multifocality. Additionally, we have no information regarding hereditary cancer syndromes; however, monogenic syndromes such as Von Hippel-Lindau syndrome are rare and are believed to represent approximately 1% of kidney cancers. These features have been previously established as significant predictors for the development of metachronous RCC and impart limitations on the clinical use of our model. 4 It should be mentioned that patients who have a hereditary cancer syndrome undergo lifelong surveillance, which may influence recurrence identification with long-term follow-up. Additionally, tumor histologies were not assessed under central pathology review and are liable to interobserver disagreement. It should also be noted that we were limited to pathologically confirmed diagnoses. Because our study encompasses only histologically confirmed disease, patients without histologic diagnosis (eg, those managed by surveillance or ablation) were not captured, which may result in an underestimation of incidence. Patients who developed radiographic evidence of metachronous, contralateral RCC may have decided against further diagnostic confirmation. 18 Surveillance for disease recurrence may increase RCC detection in patients with a prior diagnosis compared with the general population. However, because many of the bilateral, metachronous tumors developed long after the end of the routine follow-up period, it is unclear how significant the pattern of detection differs in this population. Despite these limitations, our large sample size along with demographic and tumor information has allowed us to describe important associations and predictors of bilateral, metachronous RCC.
In conclusion, when compared with the general population, patients with localized or regional RCC have a significantly increased risk of developing an additional RCC regardless of race, age, or sex. The overall cumulative incidence of bilateral, metachronous RCC was 4.7% after a 30-year follow-up, which is higher than previous estimates. Specific characteristics that further increase the risk of developing a metachronous, contralateral RCC include black race, younger age, male sex, and papillary histology. Our data suggest that the majority of metachronous, contralateral kidney tumors develop beyond 5 years of follow-up, which may provide a rationale for lifetime RCC screening in high-risk patients.
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